Overview

Predicting Response to Iron Supplementation in Patients With Inflammatory Bowel Disease During Induction Therapy

Status:
Not yet recruiting

Trial end date:
2023-08-31

Target enrollment:

Participant gender:

Summary

Iron deficiency anemia is the most common systemic manifestation of Inflammatory Bowel Diseases (IBD)-Crohn's disease and ulcerative colitis. Iron deficiency with or without anemia poses a diagnostic and therapeutic challenge due to chronic gastrointestinal blood loss and the inflammatory nature of IBD. Recent illumination of iron metabolism has brought attention to the systemic iron regulator-hepcidin, a peptide hormone that regulates intestinal iron absorption and systemic iron availability. Elevated hepcidin is associated with oral iron malabsorption in IBD. This study aims to evaluate whether hepcidin concentration at baseline can predict response to oral and intravenous iron therapy in patients with IBD and concomitant iron deficiency with or without anemia.

Phase:

Phase 4

Details

Lead Sponsor:

Leiden University Medical Center

Collaborators:

Maastricht University Medical Center
Radboud University Medical Center
University Medical Center Groningen

Treatments:

Ferric maltol
Ferrous fumarate
Iron